3.91  0.06 (1.56%)		06-09 16:00
Open: 3.81 High: 4 Volume: 166,933		Pre. Close: 3.85 Low: 3.7001 Market Cap: 107(M)

Short term
Mid term
Targets	6-month :	5.42	1-year :	6.11
Resists	First :	4.64	Second :	5.23
Pivot price	4.35
Supports	First :	3.7	Second :	3.07
MAs	MA(5) :	3.99	MA(20) :	4.38
	MA(100) :	3.13	MA(250) :	1.94
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	8.3	D(3) :	9.2
RSI	RSI(14): 40.7
52-week	High :	6.9	Low :	1

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ANTX ] has closed above bottom band by 17.8%. Bollinger Bands are 18.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4 - 4.02	4.02 - 4.04
Low:	3.66 - 3.68	3.68 - 3.69
Close:	3.88 - 3.91	3.91 - 3.94

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Tue, 09 Jun 2026
AN2 rises after early-stage trial data for Chagas disease therapy - MSN

Mon, 08 Jun 2026
Shareholders back AN2 Therapeutics (NASDAQ: ANTX) directors and auditor - Stock Titan

Thu, 04 Jun 2026
AN2 Therapeutics (Nasdaq: ANTX) posts strong early Chagas trial data - Stock Titan

Thu, 04 Jun 2026
ANTX: Three phase II programs targeting major unmet needs will deliver key data readouts starting this year - TradingView

Thu, 04 Jun 2026
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire

Tue, 02 Jun 2026
AN2 Therapeutics (ANTX) officer sells 265 shares to cover RSU taxes - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	36 (M)
Shares Float	17 (M)
Held by Insiders	18.8 (%)
Held by Institutions	70.4 (%)
Shares Short	836 (K)
Shares Short P.Month	634 (K)

EPS	-1.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.26
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-27.5 %
Return on Equity (ttm)	-44.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-31 (M)
Levered Free Cash Flow	-19 (M)

PE Ratio	-3.56
PEG Ratio	0
Price to Book value	1.72
Price to Sales	0
Price to Cash Flow	-4.51

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.